As the global economy mends, the 2021 growth of Personalized Cancer Vaccines will have significant change from previous year. According to our (LP Information) latest study, the global Personalized Cancer Vaccines market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Personalized Cancer Vaccines market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Personalized Cancer Vaccines market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Personalized Cancer Vaccines market, reaching US$ million by the year 2028. As for the Europe Personalized Cancer Vaccines landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Personalized Cancer Vaccines players cover Advaxis Inc, Personalis, Hoffmann-La Roche Ltd, and BioNtech, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Personalized Cancer Vaccines market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Prostate Cancer
Cervical Cancer
Glioblastoma
Others
By Mechanism of Action Type
Tumor-associated antigens (TAAs)
Tumor-specific antigens (TSAs)
Somatic Mutations in Cancer Pharmacogenomics
Pharmacogenomics towards Genomic Polymorphism
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospitals
Homecare
Specialty Clinics
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Advaxis Inc
Personalis
Hoffmann-La Roche Ltd
BioNtech
Celldex
CureVac AG
Genetech
Genocea
Gritstone Oncology
ISA Pharmaceuticals
Merck
Moderna Therapeutics